Attention and Intervention of Oncologists on Oxaliplatin-induced Adverse Reactions in Mainland China: A Cross-sectional Internet-based Survey

Abstract

Objective

This cross-sectional study aimed to investigate the current attention and intervention of oncologists on oxaliplatin (OXA)-induced adverse reactions (ADRs).

Methods

In 31 provinces or administrative regions across China, 401 oncologists were surveyed through a self-designed questionnaire. The survey queried the basic information of respondents, clinical use of OXA, OXA-induced ADRs, and relative interventions. Chi-square tests and multiple logistic regression were used to explore the sociodemographic factors influencing the safety perception of OXA and the relevant interventions.

Results

The survey showed that the age of respondents was mainly distributed between 30 and 40 years and the working period for most oncologists was no more than 5 years. Oncologists with long working years were more willing to conduct patient education and inquire about ADRs than those with short working years. The rate of ADRs reported by oncologists with intermediate professional titles was significantly higher than that reported by oncologists with junior and senior professional titles.

Conclusion

Our findings indicate that oncologists in mainland China are concerned about OXA-induced ADRs, but the reporting of ADRs still needs to be strengthened. Therefore, training and educational programs are urgently needed to improve the risk management of OXA-induced ADRs among oncologists.

Keywords

oxaliplatin / adverse reaction / intervention / cross-sectional survey

References

[1] de GramontA, FigerA, SeymourM, et al.. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 2000, 18: 2938-2947

[2] VyskocilJ, TucekS, KissI, et al.. Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening. Int Immunopharmacol, 2019, 74: 105728

[3] GrotheyA, GoldbergRM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother, 2004, 5(10): 2159-2170

[4] AndréT, BoniC, NavarroM, et al.. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 2009, 27: 3109-3116

[5] BensonAB, VenookAP, Al-HawaryMM, et al.. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw, 2020, 18(7): 806-815

[6] BensonAB, VenookAP, Al-HawaryMM, et al.. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2021, 19(3): 329-359

[7] MathéG, KidaniY, TrianaK, et al.. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother, 1986, 40: 372-376

[8] ExtraJ M, EspieM, CalvoF, et al.. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol, 2002, 25: 299-303

[9] CassidyJ, MissetJL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol, 2002, 29(Suppl 15): 11-20 5

[10] GrahamMA, LockwoodGF, GreensladeD, et al.. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res, 2000, 6(4): 1205-1218

[11] TofthagenC, McAllisterRD, McMillanSC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs, 2011, 15: 182-188

[12] ThomasRR, QuinnMG, SchulerB, et al.. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 2003, 97: 2301-2307

[13] StefanssonM, NygrenP. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. Acta Oncol, 2016, 55: 1227-1235

[14] DrottJ, FomichovV, StarkhammarH, et al.. Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities: A Longitudinal Study Among Patients With Colorectal Cancer. Cancer Nurs, 2019, 42: E40-E48

[15] AroldiF, ProchiloT, BertocchiP, et al.. Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management. J Chemother, 2015, 27: 63-66

[16] van MierloKM, ZhaoJ, KleijnenJ, et al.. The influence of chemotherapy-associated sinusoidal dilatation on short-term outcome after partial hepatectomy for colorectal liver metastases: A systematic review with meta-analysis. Surg Oncol, 2016, 25: 298-307

[17] NakanoH, OussoultzoglouE, RossoE, et al.. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg, 2008, 247: 118-124

[18] VautheyJN, PawlikTM, RiberoD, et al.. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol, 2006, 24: 2065-2072

[19] MathéG, KidaniY, SegiguchiM, et al.. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother, 1989, 43: 237-250

[20] DierasV, BougnouxP, PetitT, et al.. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/− taxane-pretreated ovarian cancer patients. Ann Oncol, 2002, 13: 258-266

[21] MonnetI, BrienzaS, HugretF, et al.. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques. Eur J Cancer, 1998, 34: 1124-1127

[22] WilsonRH, LehkyT, ThomasRR, et al.. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol, 2002, 20: 1767-1774

[23] YuZ, HuangR, ZhaoL, et al.. Safety Profile of Oxaliplatin in 3687 Patients With Cancer in China: A Post-Marketing Surveillance Study. Front Oncol, 2021, 11: 757196

[24] BrienzaS, VignoudJ, ItzhakiM, et al.. Oxaliplatin (LOHP): global safety in 682 patients. Proc Am Soc Clin Oncol, 1995, 14: 209(abstract 513)

[25] HewittMR, SunW. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin Colorectal Cancer, 2006, 6: 114-117

[26] SohnKH, KangDY, KimJY, et al.. Incidence and Risk of Oxaliplatin-Induced Hypersensitivity in Patients with Asymptomatic Prior Exposure: A Prospective Observational Study. J Allergy Clin Immunol Pract, 2018, 6(5): 1642-1648.e2

[27] LiM, JiangC, YangJW, et al.. Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A retrospective Multicenter Analysis. Curr Med Sci, 2021, 41(4): 827-831

[28] HoffPM, SaadED, CostaF, et al.. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer, 2012, 11: 93-100

[29] LenzG, HackerUT, KernW, et al.. Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anticancer Drugs, 2003, 14(9): 731-733

[30] HerrstedtJ. The latest consensus on antiemetics. Curr Opin Oncol, 2018, 30(4): 233-239

[31] KangL, TianY, XuS, et al.. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. J Neurol, 2021, 268(9): 3269-3282

[32] HewittMR, SunW. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin Colorectal Cancer, 2006, 6(2): 114-117

[33] ShroukhWA, ShakhatrehFM, YaseinNA, et al.. A survey on the knowledge, attitudes and practices of physicians towards pharmacovigilance in Jordanian health centres. Int Health, 2018, 10: 363-370